Literature DB >> 20964681

Unbalanced expression of the translation complex eEF1 subunits in human cardioesophageal carcinoma.

Marina Veremieva1, Antonina Khoruzhenko, Sergej Zaicev, Boris Negrutskii, Anna El'skaya.   

Abstract

BACKGROUND: The signalling role of individual subunits released from some stable translation multi-molecular complexes under unfavourable circumstances is known. The disease-related role of the translation elongation factor 1 complex (eEF1) as a whole is never researched; however, its subunits possess apparent regulatory potency. Whether the individual eEF1 subunits can exist and function in cell beyond the complex is not known.
MATERIALS AND METHODS: The protein and mRNA levels of the A1, Bα, Bβ or Bγ subunits of eEF1 were analysed by Western and Northern blot techniques in the same specimens of cardioesophageal carcinoma and correspondingly paired normal tissues. Cancer-induced changes in localization patterns of the eEF1 subunits were examined immunohistochemically.
RESULTS: Changes in different eEF1 subunits expression were found to be unbalanced, indicating cancer-related emergence of individual components of the eEF1 complex. Independent overexpression of at least one eEF1 component was observed in 72% clinical samples. Noncomplexed eEF1B subunits were also detected by immunohistochemical analysis. In the normal tissue, localization of the Bα, Bβ and Bγ subunits was nuclear-cytoplasmic while in the cancer tissue the only Bγ subunit stayed in nucleus.
CONCLUSIONS: Our data are first to indicate that the individual subunits can exist separately from the eEF1B complex in cancer tissues and that disintegration of eEF1B could be an important sign of cancer development. Nuclear localization of Bγ both in normal and in cancer tissues suggests its previously unknown nucleus-specific role in human cells.
© 2010 The Authors. European Journal of Clinical Investigation © 2010 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964681     DOI: 10.1111/j.1365-2362.2010.02404.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Proteomic analysis of NME1/NDPK A null mouse liver: evidence for a post-translational regulation of annexin IV and EF-1Bα.

Authors:  Arnaud Bruneel; Dominique Wendum; Valérie Labas; Odile Mulner-Lorillon; Joelle Vinh; Nelly Bosselut; Eric Ballot; Bruno Baudin; Chantal Housset; Sandrine Dabernat; Marie-Lise Lacombe; Mathieu Boissan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

2.  Independent overexpression of the subunits of translation elongation factor complex eEF1H in human lung cancer.

Authors:  Maryna Veremieva; Liudmyla Kapustian; Antonina Khoruzhenko; Valery Zakharychev; Boris Negrutskii; Anna El'skaya
Journal:  BMC Cancer       Date:  2014-12-03       Impact factor: 4.430

3.  EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.

Authors:  Dong-Dong Cheng; Shi-Jie Li; Bin Zhu; Shu-Min Zhou; Qing-Cheng Yang
Journal:  J Exp Clin Cancer Res       Date:  2018-03-06

Review 4.  Non-translational Connections of eEF1B in the Cytoplasm and Nucleus of Cancer Cells.

Authors:  Boris Negrutskii
Journal:  Front Mol Biosci       Date:  2020-04-09

5.  Downregulation of Methionine Cycle Genes MAT1A and GNMT Enriches Protein-Associated Translation Process and Worsens Hepatocellular Carcinoma Prognosis.

Authors:  Po-Ming Chen; Cheng-Hsueh Tsai; Chieh-Cheng Huang; Hau-Hsuan Hwang; Jian-Rong Li; Chun-Chi Liu; Hsin-An Ko; En-Pei Isabel Chiang
Journal:  Int J Mol Sci       Date:  2022-01-01       Impact factor: 5.923

6.  eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Shi-Lu Chen; Shi-Xun Lu; Li-Li Liu; Chun-Hua Wang; Xia Yang; Zhi-Yi Zhang; Hui-Zhong Zhang; Jing-Ping Yun
Journal:  Transl Oncol       Date:  2017-12-18       Impact factor: 4.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.